Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

Target Validation Information
TTD IDTTDS00017
Target NameSodium-dependent dopamine transporter    
Type of TargetSuccessful target    
Drug Potency against TargetMethylphenidateIC50 = 257 nM[1]
MethylphenidateKi = 17 nM[2]
VanoxerineIC50 = 0.8 nM[3]
RTI-336IC50 = 4.09 nM[4]
(+/-)-threo-3',4'-Dichlororitalinol methyl etherIC50 = 1.7 nM[5]
8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octaneIC50 = 10.2 nM[6]
(+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidineIC50 = 1000 nM[7]
4-(2-pyrrolidin-1-yl-pentanoyl)benzonitrileIC50 = 1000 nM[8]
1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamineIC50 = 10000 nM[9]
2-(N-Pyrrolidinyl)-3'-nitropropiophenoneIC50 = 10000 nM[10]
bip-tyr(3bzl)-thr-pro-lys-thrIC50 = 10000 nM[11]
(+/-)-threo-BenzylphenidateIC50 = 1020 nM[5]
threo-N-ethylritalinol hydrochlorideIC50 = 10400 nM[12]
(+/-)-threo-N-(3-Chlorobenzyl)methylphenidateIC50 = 106 nM[5]
1-benzylpiperidine hydrochlorideIC50 = 1060 nM[12]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-olIC50 = 1065 nM[13]
(+/-)-threo-N-Methyl-30-methylmethylphenidateIC50 = 108 nM[5]
HOMOAROMOLINEIC50 = 10900 nM[14]
DIMETHYLGRISABINEIC50 = 1100 nM[14]
1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazineIC50 = 11000 nM[15]
bip-tyr-ala-pro-lys-thr(obzl)-glyIC50 = 11000 nM[11]
1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-oneIC50 = 1110 nM[8]
(+/-)-threo-N-(4-Nitrobenzyl)methylphenidateIC50 = 113 nM[5]
1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidineIC50 = 12 nM[16]
1-Benzo[b]thiophen-2-yl-cyclohexylamineIC50 = 123 nM[17]
(+/-)-threo-N-(4-Methylpyridine)methylphenidateIC50 = 128 nM[5]
1-(2-(2-chlorophenyl)-1-phenylethyl)piperazineIC50 = 1300 nM[15]
SECOCULARIDINEIC50 = 13400 nM[14]
2-(N-tert-Butylamino)-3'-chlorooctanophenoneIC50 = 135 nM[18]
3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenolIC50 = 1400 nM[15]
NORSTEPHALAGINEIC50 = 1400 nM[14]
COCLAURINEIC50 = 14100 nM[14]
(+/-)-threo-N-(3-Methylthiopene)methylphenidateIC50 = 143 nM[5]
(+/-)-threo-N-(2-Phenylethyl)ritalinolIC50 = 1430 nM[5]
METHYLENEDIOXYMETHAMPHETAMINEIC50 = 1442 nM[19]
2-Aminomethyl-5-(phenyl)tetrahydrofuranIC50 = 147 nM[20]
2-(tert-butylamino)-1-m-tolylpropan-1-oneIC50 = 1470 nM[10]
(RS/SR)-2-[1-(4-chlorophenyl)ethyl]piperidineIC50 = 1500 nM[21]
(S)-3-(naphthalen-2-ylmethoxy)pyrrolidineIC50 = 15000 nM[7]
threo-ritalinol hydrochlorideIC50 = 1520 nM[12]
2-(N-Pyrrolidinyl)-3'-fluoropropiophenoneIC50 = 156 nM[10]
(+/-)-threo-N-(5-Phenylpentyl)methylphenidateIC50 = 1570 nM[5]
(+/-)-threo-3',4'-Dichloromethylphenidate amideIC50 = 16.4 nM[5]
NORBOLDINEIC50 = 16500 nM[14]
2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuranIC50 = 167 nM[20]
(RS/SR)-2-[1-(4-chlorophenyl)pentyl]piperidineIC50 = 170 nM[21]
bip-tyr-thr-pro-ala-thr(obzl)-glyIC50 = 1700 nM[11]
(+/-)-threo-N-(3-Methylpyridine)methylphenidateIC50 = 173 nM[5]
(+/-)-threo-Methylphenidate amideIC50 = 1730 nM[5]
2-(N,N-Diethylamino)-3'-chloropropiophenoneIC50 = 1744 nM[18]
2-(tert-Butylamino)-3',4'-dichlorobutyrophenoneIC50 = 175 nM[18]
1-(3-chlorophenyl)-2-(dimethylamino)propan-1-oneIC50 = 1750 nM[10]
1-(1-Benzo[b]thiophen-2-yl-cyclohexyl)-azepaneIC50 = 18 nM[17]
bip-tyr-thr-pro-lys-thr(obzl)-glyIC50 = 1800 nM[11]
1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-oneIC50 = 185 nM[8]
1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexaneIC50 = 190 nM[22]
1-phenyl-1-(piperidin-2-yl)propan-2-oneIC50 = 190 nM[21]
bip-tyr-thr-pro-lys-thrIC50 = 19000 nM[11]
(+/-)-threo-N-(3-Phenylpropyl)ritalinolIC50 = 194 nM[5]
2-(tert-butylamino)-1-p-tolylpropan-1-oneIC50 = 1950 nM[10]
(+/-)-threo-N-Benzyl-3',4'-dichlororitalinolIC50 = 2.74 nM[5]
cis-3-phenoxy-2,3-dihydro-1H-inden-1-amineIC50 = 2000 nM[23]
(+/-)-threo-N-(4-Phenylbutyl)methylphenidateIC50 = 205 nM[5]
2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-oneIC50 = 209 nM[10]
1-(1-Benzo[b]thiophen-2-yl-cyclopentyl)-azepaneIC50 = 21 nM[17]
WIN_35428IC50 = 21 nM[24]
threo-3,4-dichlororitalinol hydrochlorideIC50 = 22.5 nM[12]
(+/-)-threo-N-(2-Methylthiopene)methylphenidateIC50 = 224 nM[5]
2-(N-Cyclopentylamino)-3'-methoxypropiophenoneIC50 = 2270 nM[10]
WIN-35065IC50 = 23 nM[25]
WIN-35065-2IC50 = 23 nM[24]
WIN-35066-2IC50 = 23 nM[26]
3alpha-(bis-chloro-phenylmethoxy)tropaneIC50 = 23.4 nM[27]
DEXMETHYLPHENIDATE HYDROCHLORIDEIC50 = 230 nM[12]
1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexaneIC50 = 2300 nM[22]
(+/-)-threo-N-EthylritalinolIC50 = 2340 nM[5]
NISOXETINEIC50 = 2400 nM[23]
(+/-)-threo-N-(2-Chlorobenzyl)methylphenidateIC50 = 243 nM[5]
threo-1-aza-5-phenyl[4.4.0]decane hydrochlorideIC50 = 244 nM[12]
(+/-)-threo-N-3-ChlorobenzylmethylphenidateIC50 = 25.8 nM[5]
ISOPILINEIC50 = 2500 nM[14]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-olIC50 = 2600 nM[13]
2-(N-Cyclopropylamino)-3-chloropropiophenoneIC50 = 265 nM[18]
(+/-)-threo-N-(3-Phenylpropyl)methylphenidateIC50 = 267 nM[5]
1-phenyl-3-aza-bicyclo[3.1.0]hexaneIC50 = 2700 nM[22]
2-(N-tert-Butylamino)-3',4'-dichloropropiophenoneIC50 = 271 nM[18]
2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuranIC50 = 28 nM[20]
(RS/SR)-2-[1-(4-chlorophenyl)propyl]piperidineIC50 = 2800 nM[21]
(+/-)-threo-3-FluororitalinolIC50 = 281 nM[5]
threo-ritalinol methyl ether hydrochlorideIC50 = 281 nM[12]
bip-tyr-thr-pro-thr(obzl)-glyIC50 = 300 nM[11]
2-Amino-1-(4-methylthiophenyl)propaneIC50 = 3073 nM[19]
(+/-)-threo-N-(4-Chlorobenzyl)methylphenidateIC50 = 31.2 nM[5]
2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuranIC50 = 313 nM[20]
erythro-3,4-dichloromethylphenidate hydrochlorideIC50 = 317 nM[12]
1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-oneIC50 = 32 nM[8]
PYROVALERONEIC50 = 32 nM[28]
1S,2R-milnacipranIC50 = 3200 nM[29]
2-(N-tert-Butylamino)-3'-chloropentanophenoneIC50 = 33 nM[18]
3-p-Tolyl-8-aza-bicyclo[3.2.1]octaneIC50 = 33.6 nM[6]
1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexaneIC50 = 330 nM[22]
ANTIOQUINEIC50 = 3400 nM[14]
(+/-)-threo-N-(2-Methylpyridine)methylphenidateIC50 = 369 nM[5]
AMINOBENZTROPINEIC50 = 373 nM[30]
1-(3,4-dichlorophenyl)-3-aza-bicyclo[3.1.0]hexaneIC50 = 380 nM[22]
(R)-3-(naphthalen-2-ylmethoxy)pyrrolidineIC50 = 3800 nM[7]
2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamineIC50 = 3800 nM[9]
(+/-)-threo-N-Benzylmethylphenidate amideIC50 = 384 nM[5]
1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-oneIC50 = 39.5 nM[8]
6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinolineIC50 = 3900 nM[22]
OBABERINEIC50 = 3900 nM[14]
(+/-)-threo-3',4'-DichlororitalinolIC50 = 4.2 nM[5]
1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-oneIC50 = 40 nM[8]
1-(1,4-diphenylbutan-2-yl)piperazineIC50 = 400 nM[31]
COCAINE.HCLIC50 = 404 nM[12]
(+/-)-threo-N-Benzyl-3'-chloromethylphenidateIC50 = 41.2 nM[5]
2-(N-Pyrrolidinyl)-3'-methylpropiophenoneIC50 = 414 nM[10]
1-Benzo[b]thiophen-2-yl-cycloheptylamineIC50 = 416 nM[17]
ISOTETRANDRINEIC50 = 4200 nM[14]
para-chloroamphetamineIC50 = 424 nM[19]
2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuranIC50 = 4301 nM[20]
(+/-)-threo-RitalinolIC50 = 448 nM[5]
(RS/SR)-2-[1-(4-chlorophenyl)butyl]piperidineIC50 = 450 nM[21]
N,Ndimethyl milnacipranIC50 = 4500 nM[32]
2-(N-Pyrrolidinyl)-3'-methoxypropiophenoneIC50 = 452 nM[10]
(+/-)-threo-N-(3-Methylfuran)methylphenidateIC50 = 459 nM[5]
2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuranIC50 = 463 nM[20]
(+/-)-threo-3',5'-DimethylmethylphenidateIC50 = 4690 nM[5]
RTI-219IC50 = 5.7 nM[25]
1-(3-bromophenyl)-2-(tert-butylamino)propan-1-oneIC50 = 511 nM[10]
2-(Aminomethyl)-5-phenethyltetrahydrofuranIC50 = 513 nM[20]
1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-oneIC50 = 52 nM[8]
2pyrrolidin-1-yl-1-phenylpentan-1-oneIC50 = 52.3 nM[8]
N-BenzylmethylphenidateIC50 = 52.9 nM[5]
(+/-)-threo-N-(2-Methylfuran)methylphenidateIC50 = 536 nM[5]
2-(tert-Butylamino)-3',5'-difluoropropiophenoneIC50 = 5600 nM[18]
2-(2'-Aminoethyl)-5-benzyltetrahydrofuranIC50 = 565 nM[20]
O-methyldauricineIC50 = 5800 nM[14]
(+/-)-threo-N-AllylmethylphenidateIC50 = 597 nM[5]
trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amineIC50 = 600 nM[23]
6-(piperidin-4-ylmethoxy)-2-naphthonitrileIC50 = 6000 nM[7]
[N-[2-[(3'-N'-PROPYL-3''ALPHA-(BIS(4-FLUORORPHENYL)METHOXY)TROPANE-2''BETA-CARBOXYLIC ACID METHYL ESTER)(2-MERCAPTOETHYL)AMINO]ACETYL]-2-AMINOETHANETHIOLATO]RHENIUM(V) OXIDE (DIASTEREOMERIC MIX)IC50 = 616 nM[33]
1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-oneIC50 = 62.9 nM[8]
(+/-)-threo-N-(4-Phenylbutyl)ritalinolIC50 = 623 nM[5]
1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-oneIC50 = 63 nM[8]
1-Benzo[b]thiophen-2-yl-cyclopentylamineIC50 = 630 nM[17]
(S)-NorfluoxetineIC50 = 6488 nM[34]
(+/-)-threo-3',5'-DichloromethylphenidateIC50 = 65.6 nM[5]
(RS/SR)-2-[1-(4-chlorophenyl)hexyl]piperidineIC50 = 650 nM[21]
(+/-)-threo-N-(6-Phenylhexyl)methylphenidateIC50 = 656 nM[5]
(R)-DULOXETINEIC50 = 660 nM[35]
2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuranIC50 = 668 nM[20]
1-(1-Benzo[b]thiophen-2-yl-cycloheptyl)-azepaneIC50 = 67 nM[17]
LITOXETINEIC50 = 6700 nM[36]
(+/-)-threo-N-(2-Phenylethyl)methylphenidateIC50 = 678 nM[5]
1-(4-bromophenyl)-2-(tert-butylamino)propan-1-oneIC50 = 689 nM[10]
2-(N-tert-Butylamino)-3'-chlorohexanophenoneIC50 = 69 nM[18]
(+/-)-threo-Ritalinol acetateIC50 = 690 nM[5]
2-(N-Cyclopentylamino)-3'-fluoropropiophenoneIC50 = 693 nM[10]
1-(4-aminophenyl)-2-pyrrolidin-1-yl-pentan-1-oneIC50 = 7 nM[28]
(R)-NorfluoxetineIC50 = 7133 nM[34]
(+/-)-threo-4'-EthylmethylphenidateIC50 = 737 nM[5]
2-(N-Pyrrolidinyl)-3'-bromopropiophenoneIC50 = 750 nM[10]
1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexaneIC50 = 7500 nM[22]
(+/-)-threo-N-(4-Methoxybenzyl)methylphenidateIC50 = 79.1 nM[5]
ANONAINEIC50 = 800 nM[14]
ANOLOBINEIC50 = 8100 nM[14]
(+/-)-threo-N-PropargylmethylphenidateIC50 = 821 nM[5]
DEXMETHYLPHENIDATEIC50 = 83 nM[5]
2-(N-Cyclopentylamino)-3'-methylpropiophenoneIC50 = 842 nM[10]
2-(N-Cyclopentylamino)-3'-bromopropiophenoneIC50 = 845 nM[10]
1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-oneIC50 = 852 nM[10]
(cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexaneIC50 = 8700 nM[22]
2-phenylpiperidine hydrochlorideIC50 = 8800 nM[12]
7-(piperidin-4-ylmethoxy)-2-naphthonitrileIC50 = 8800 nM[7]
METHYLENEDIOXYAMPHETAMINEIC50 = 890 nM[37]
bip-tyr-thr-ala-pro-pheIC50 = 900 nM[11]
(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamideIC50 = 9500 nM[36]
(+/-)-threo-Ritalinol methyl etherIC50 = 97.1 nM[5]
2-(N-Cyclopentylamino)-3'-chloropropiophenoneIC50 = 980 nM[18]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-oneKi < 1000 nM[38]
GBR-12909Ki = 1.77 nM[39]
D-254CKi = 10.6 nM[40]
4-(2-(benzyloxy)phenyl)piperidineKi = 1000 nM[41]
4-(2-(benzyloxy)-6-fluorophenyl)piperidineKi = 1030 nM[41]
3-(4-Fluorophenyl)-2-nortropeneKi = 1056 nM[42]
4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidineKi = 1080 nM[41]
1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-olKi = 11 nM[43]
10S-hydroxylobel-7-eneKi = 110 nM[44]
3-alpha-Phenylmethoxy-3-beta-phenyl-nortropaneKi = 117 nM[42]
3-Phenyl-2-nortropeneKi = 1222 nM[42]
8S-hydroxylobelaneKi = 1260 nM[44]
4-(2-(4-fluorophenoxy)phenyl)piperidineKi = 13 nM[41]
PSEUDOCOCAINEKi = 13800 nM[45]
4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidineKi = 139 nM[41]
10S-hydroxylobelaneKi = 1390 nM[44]
4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidineKi = 1450 nM[41]
(2S,3S)-iodoreboxetineKi = 1457 nM[46]
3-(4-Trifluoromethylphenyl)-2-nortropeneKi = 1494 nM[42]
3-(3,4-dichlorophenyl)-2-nortropeneKi = 16 nM[42]
4-(2-(3-fluorophenoxy)phenyl)piperidineKi = 166 nM[41]
4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidineKi = 1680 nM[41]
(1-Phenyl-ethyl)-(2-phenyl-quinazolin-4-yl)-amineKi = 1800 nM[47]
4-(2-(2-fluorobenzyloxy)phenyl)piperidineKi = 1810 nM[41]
8R-hydroxylobelaneKi = 1880 nM[44]
(2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholineKi = 1900 nM[48]
1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazineKi = 1950 nM[49]
[3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amineKi = 2 nM[43]
D-257AKi = 204 nM[40]
(R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenolKi = 2070 nM[49]
(2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholineKi = 2100 nM[48]
2-(N-tert-Butylamino)-4'-chloropropiophenoneKi = 2195 nM[18]
PF-3409409Ki = 2290 nM[50]
3-(4-Chlorophenyl)-2-nortropeneKi = 231 nM[42]
4-(3-fluoro-2-phenoxyphenyl)piperidineKi = 239 nM[41]
Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amineKi = 2470 nM[51]
1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)Ki = 2620 nM[49]
PF-526014Ki = 2650 nM[49]
4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidineKi = 278 nM[52]
4-(2-phenoxyphenyl)piperidineKi = 284 nM[41]
10R-hydroxylobel-7-eneKi = 290 nM[44]
4-(2-(3-chlorophenoxy)phenyl)piperidineKi = 310 nM[41]
1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX)Ki = 3160 nM[49]
R-NORDULOXETINEKi = 3549 nM[53]
4-(2-(phenoxymethyl)phenyl)piperidineKi = 396 nM[41]
2-(N-Isopropylamino)-3'-chloropropiophenoneKi = 3980 nM[18]
DIFLUOROBENZTROPINEKi = 4.11 nM[27]
1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-olKi = 40 nM[43]
methyl 2-(naphthalen-2-yl)benzoateKi = 4060 nM[54]
D-211AKi = 41.8 nM[40]
2-((2-iodophenoxy)(phenyl)methyl)morpholineKi = 410 nM[55]
(RS/SR)-2-[1-(3,4-dichlorophenyl)butyl]piperidineKi = 43 nM[21]
2-(tert-Butylamino)-3',4'-dichloropentanophenoneKi = 43.7 nM[18]
2-phenoxy-3-(piperidin-4-yl)pyridineKi = 4310 nM[52]
8R-hydroxylobel-9-eneKi = 44 nM[56]
1-(2-(4-fluorophenoxy)phenyl)piperazineKi = 4420 nM[41]
4-(2-fluoro-6-phenoxyphenyl)piperidineKi = 45 nM[41]
2-(tert-Butylamino)-3'-fluoropropiophenoneKi = 4510 nM[18]
4-(2-((3-fluorophenoxy)methyl)phenyl)piperidineKi = 461 nM[41]
1-(2-phenoxyphenyl)piperazineKi = 4730 nM[41]
2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridineKi = 5150 nM[52]
(2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholineKi = 525.9 nM[48]
Benzhydryl-(2-phenyl-quinazolin-4-yl)-amineKi = 530 nM[47]
PF-18298;PF-184298Ki = 544 nM[49]
10R-hydroxylobelaneKi = 570 nM[44]
2-(N-tert-Butylamino)propiophenoneKi = 5730 nM[18]
R-226161Ki = 583 nM[57]
GB-12819Ki = 595 nM[58]
4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidineKi = 6 nM[41]
(1-Phenyl-ethyl)-(2-phenyl-quinazolin-4-yl)-amineKi = 6100 nM[47]
2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridineKi = 6410 nM[52]
D-257CKi = 66.5 nM[40]
1-(2-(phenoxymethyl)phenyl)piperazineKi = 701 nM[41]
2-(N-tert-Butylamino)-3'-chloroheptanophenoneKi = 709 nM[18]
(2R,3R)-iodoreboxetineKi = 716 nM[46]
4-(2-(benzyloxy)-3-fluorophenyl)piperidineKi = 7370 nM[41]
2-((3-iodophenyl)(o-tolyloxy)methyl)morpholineKi = 740 nM[55]
FLUOXETINE HYDROCHLORIDEKi = 784 nM[59]
Benzyl-(2-phenyl-quinazolin-4-yl)-amineKi = 7900 nM[47]
D-211BKi = 8.63 nM[40]
D-166AKi = 82.9 nM[40]
4-(2-(4-fluorobenzyloxy)phenyl)piperidineKi = 9120 nM[41]
8S-hydroxylobel-9-eneKi = 960 nM[44]
Ref 1J Pharmacol Exp Ther. 1991 May;257(2):830-5.Interactions of [3H]amphetamine with rat brain synaptosomes. II. Active transport. To Reference
Ref 2Curr Top Med Chem. 2006;6(17):1845-59.Therapeutic potential of monoamine transporter substrates. To Reference
Ref 3J Cardiovasc Electrophysiol. 2010 Mar;21(3):311-9. Epub 2009 Oct 8.Vanoxerine, a new drug for terminating atrial fibrillation and flutter. To Reference
Ref 4Eur J Pharmacol. 2006 Dec 28;553(1-3):149-56. Epub 2006 Sep 23.Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration. To Reference
Ref 5Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. Epub 2010 Aug 19.Quantitative structure-activity relationship studies of threo-methylphenidate analogs. To Reference
Ref 6Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7.3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. To Reference
Ref 7Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. Epub 2009 Feb 20.Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. To Reference
Ref 8J Med Chem. 2006 Feb 23;49(4):1420-32.1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. To Reference
Ref 9J Med Chem. 1986 Aug;29(8):1406-12.Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-aminoethyl)-2,3-dihydroindoles. To Reference
Ref 10J Med Chem. 2010 Mar 11;53(5):2204-14.Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. To Reference
Ref 11J Med Chem. 2006 Jul 13;49(14):4048-51.Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. To Reference
Ref 12J Med Chem. 2007 May 31;50(11):2718-31. Epub 2007 May 10.Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. To Reference
Ref 13J Med Chem. 2010 Jun 24;53(12):4731-48.Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. To Reference
Ref 14J. Nat. Prod. 58(10):1475-1484 (1995) To Reference
Ref 15Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. Epub 2006 Jun 5.N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. To Reference
Ref 16J Med Chem. 2008 Jul 24;51(14):4150-69. Epub 2008 Jun 28.Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. To Reference
Ref 17J Med Chem. 1993 Apr 30;36(9):1188-93.Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-binding sites. To Reference
Ref 18J Med Chem. 2009 Nov 12;52(21):6768-81.Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. To Reference
Ref 19Eur J Med Chem. 2009 Dec;44(12):4862-88. Epub 2009 Aug 6.Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. To Reference
Ref 20Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. Epub 2009 Jan 15.2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. To Reference
Ref 21J Med Chem. 2007 Jan 25;50(2):219-32.Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. To Reference
Ref 22Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. Epub 2008 May 23.Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. To Reference
Ref 23Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7. Epub 2008 May 20.Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). To Reference
Ref 24J Med Chem. 1996 Oct 11;39(21):4139-41.3 alpha-(4'-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters: novel ligands with high affinity and selectivity at the dopamine transporter. To Reference
Ref 25J Med Chem. 2007 Jul 26;50(15):3686-95. Epub 2007 Jun 30.Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-[5-(substituted phenyl)thiazol-2-yl]tropanes. To Reference
Ref 26J Med Chem. 2004 Dec 2;47(25):6401-9.Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers. To Reference
Ref 27J Med Chem. 2006 Oct 19;49(21):6391-9.Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogues for in vivo investigation. To Reference
Ref 28Bioorg Med Chem. 2009 Jun 1;17(11):3770-4. Epub 2009 May 3.A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone. To Reference
Ref 29J Med Chem. 2008 Nov 27;51(22):7265-72.Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. To Reference
Ref 30J Med Chem. 1997 Mar 14;40(6):851-7.3'-Chloro-3 alpha-(diphenylmethoxy)tropane but not 4'-chloro-3 alpha-(diphenylmethoxy)tropane produces a cocaine-like behavioral profile. To Reference
Ref 31Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53. Epub 2006 Jun 5.Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. To Reference
Ref 32Bioorg Med Chem Lett. 2008 Feb 15;18(4):1346-9. Epub 2008 Jan 9.Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. To Reference
Ref 33J Med Chem. 1997 Jun 6;40(12):1835-44.A technetium-99m SPECT imaging agent which targets the dopamine transporter in primate brain. To Reference
Ref 34Bioorg Med Chem. 2009 Jan 1;17(1):337-43. Epub 2008 Nov 5.Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. To Reference
Ref 35Bioorg Med Chem Lett. 2009 Jan 1;19(1):58-61. Epub 2008 Nov 13.1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors. To Reference
Ref 36Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. To Reference
Ref 37Bioorg Med Chem. 2010 Jun 1;18(11):4009-31. Epub 2010 Apr 13.Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioamphetamines. To Reference
Ref 38J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. To Reference
Ref 39Bioorg Med Chem Lett. 2008 Oct 1;18(19):5238-41. Epub 2008 Aug 22.Dual DAT/sigma1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol. To Reference
Ref 40Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. Epub 2008 Jan 11.Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an exocyclic hydroxyl group: interaction with dopamine, serotonin, and norepinephrine transporters. To Reference
Ref 41Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists. To Reference
Ref 42Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. Epub 2009 Oct 23.Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. To Reference
Ref 43J Med Chem. 2004 May 6;47(10):2624-34.Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. To Reference
Ref 44Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. Epub 2006 Aug 14.Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. To Reference
Ref 45Bioorg Med Chem Lett. 1999 Jul 5;9(13):1831-6.Synthesis of 8-Oxa analogues of norcocaine endowed with interesting cocaine-like activity. To Reference
Ref 46Bioorg Med Chem Lett. 2008 Sep 15;18(18):4940-3. Epub 2008 Aug 19.New iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. To Reference
Ref 47Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8.Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. To Reference
Ref 48Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8. Epub 2009 Jul 16.Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. To Reference
Ref 49Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. Epub 2010 Apr 18.Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. To Reference
Ref 50Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83. Epub 2009 Jul 2.Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template. To Reference
Ref 51Bioorg Med Chem Lett. 2008 Aug 1;18(15):4355-9. Epub 2008 Jun 25.Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity. To Reference
Ref 52Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. Epub 2009 Dec 6.Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists. To Reference
Ref 53Bioorg Med Chem. 2009 Oct 1;17(19):6890-7. Epub 2009 Aug 20.Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. To Reference
Ref 54Bioorg Med Chem. 2007 Jun 15;15(12):4159-74. Epub 2007 Mar 30.Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters. To Reference
Ref 55Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7. Epub 2006 Oct 12.Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. To Reference
Ref 56Bioorg Med Chem. 2010 Jan 15;18(2):640-9. Epub 2009 Dec 6.Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters. To Reference
Ref 57Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. Epub 2007 Mar 21.Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-adrenoceptor antagonism. To Reference
Ref 58Bioorg Med Chem Lett. 2002 Sep 2;12(17):2387-90.Synthesis and dopamine transporter binding affinities of 3alpha-benzyl-8-(diarylmethoxyethyl)-8-azabicyclo[3.2.1]octanes. To Reference
Ref 59Bioorg Med Chem. 2010 Dec 1;18(23):8356-64. Epub 2010 Sep 29.Synthesis and structure-activity studies of benzyl ester meperidine and normeperidine derivatives as selective serotonin transporter ligands. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543